Comparison of the structure-activity relationships of nociceptin and dynorphin A using chimeric peptides  by Lapalu, Sophie et al.
FEBS 19466 FEBS Letters 417 (1997) 333-336 
Comparison of the structure-activity relationships of nociceptin and 
dynorphin A using chimeric peptides 
Sophie Lapalu, Christiane Moisand, Honore Mazarguil, Gilles Cambois, Catherine Mollereau, 
Jean-Claude Meunier* 
Unite de Neuropharmacologie Moleculaire, Institut de Pharmacologie et de Biologie Structurale, Centre National de la Recherche Scientifique, 
205 route de Narbonne, 31077 Toulouse cedex 4, France 
Received 7 October 1997 
Abstract The aim of the present study was to delineate the 
functional domains of nociceptin (noc), a neuropeptide which is 
structurally related to dynorphin A (dyn). The binding and 
biological potencies towards the nociceptin (ORL1) and dynor-
phin A (ir-opioid) receptors of twenty dyn/noc and noc/dyn hybrid 
peptides were compared with those of the parent heptadecapep-
tides. Replacement of as many as eleven residues in the 
C-terminus of dynorphin by the corresponding nociceptin 
sequence has no significant effect on binding and biological 
activity towards the K-opioid receptor. In marked contrast, 
replacement of as few as six residues (RKLANQ) in the C-
terminus of nociceptin by the corresponding dynorphin sequence 
(LKWDNQ) dramatically impairs both affinity and activity 
towards the ORL1 receptor. This clearly indicates that the two 
neuropeptides have different functional architectures, despite the 
dual structural homology of both ligands and receptors. More-
over, the recombinant peptide approach led us to identify hybrids 
whose sequences differ only at positions 5 and 6 and displaying 
opposite or no receptor selectivity. One contains the dynorphin 
Leu5-Arg6 sequence and prefers the K"-opioid receptor, whereas 
the other comprises the nociceptin Thr5-Gly6 sequence and 
prefers the ORL1 receptor. A third, containing the mixed 
dynorphin/nociceptin Leu -Gly6 sequence, does not discriminate 
between the two types of receptor. 
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1. Introduction 
Nociceptin [1] or orphanin FQ [2] is the endogenous agonist 
of the ORL1 (opioid receptor-like 1) receptor, an orphan G 
protein-coupled receptor whose human [3] and murine [4-10] 
cDNAs had been identified previously. 
The ORL1 receptor is a member of the structural family of 
opioid receptors. Multiple sequence alignment places the 
ORL1 receptor equally distant (~60% homology) from the 
u,-, 8- and K-opioid receptor types. However, ORL1 and the K-
opioid receptors display a common physicochemical feature, 
not found in the two other types of opioid receptor, a highly 
acidic second exofacial loop. This loop has been shown to be 
critical for the K-opioid receptor to bind dynorphin A, its 
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putative natural agonist, a highly basic heptadecapeptide, 
with high affinity and selectivity [11,12]. 
Nociceptin/orphanin FQ, the endogenous ligand of the 
ORL1 receptor was recently isolated from brain extracts as 
a component that inhibits adenylyl cyclase in recombinant 
CHO cells expressing the orphan receptor [1,2]. Nociceptin, 
FGGFTGARKSARKLANQ, is a peptide which resembles 
dynorphin A, YGGFLRRIRPKLKWDNQ, in several re-
spects: it has the same length (17 amino acids), six identical 
amino acids (underlined), and is highly cationic. Based upon 
the dual homology, of receptors and of peptide ligands, it has 
been proposed [1] that the structural requirements for noci-
ceptin and dynorphin A to bind the ORL1 and K-opioid re-
ceptors, respectively, are very similar, if not identical. This 
hypothesis has been investigated here using the 'recombinant' 
ligand approach. Twenty nociceptin/dynorphin (nd) and dy-
norphin/nociceptin (dn) hybrid heptadecapeptides were syn-
thesized and compared with the two parent peptides in terms 
of their ability to bind and stimulate the ORL1 and K-opioid 
receptors. The results clearly indicate that nociceptin and dy-
norphin A have different functional architectures. They also 
identify amino acid residues in the two neuropeptides, that are 
important in bestowing ORL1/K-opioid receptor selectivity. 
2. Materials and methods 
2.1. Recombinant cell lines and membrane preparations 
Recombinant CHO cell lines expressing the human ORL1 and K-
opioid receptors and membrane preparations derived therefrom were 
obtained as previously described [13]. The K-opioid receptor cDNA 
was kindly provided by Dr. Brigitte Kieffer (E.S.B.S., Illkirch). 
2.2. Binding and competition studies 
[3H]diprenorphine (1.52 TBq/mmol, Amersham) was used to probe 
the K-opioid receptor site, and [3H]nociceptin (0.85 Tbq/mmol, Amer-
sham) to probe the ORL1 binding site. To minimize peptide loss due 
to nonspecific adsorption and or proteolytic degradation, stock solu-
tions and intermediate dilutions of peptide for use in the competition 
studies were made up in 0.1 mg/ml proteinase-free BSA (fraction V, 
Sigma) in polypropylene tubes, and glass fiber disks (Whatman GF/B) 
pre-soaked in polyethyleneimine (0.33%, v:v) used. Under these con-
ditions, we verified that the presence of peptidase and proteinase in-
hibitors in the assay was unnecessary. Each incubation mixture 
(0.5 ml, in triplicate) contained =30 ug membrane protein, 
[3H]diprenorphine or [3H]nociceptin at the fixed concentration of 
1 nM, and the unlabelled peptide at the desired concentration, in 50 
mM Tris-HCl, pH 7.5. Nonspecific binding (<20% of total binding 
for the two radioligands) was determined in the presence of 1 uM 
unlabelled diprenorphine or nociceptin. Following a 1 h incubation at 
25°C, unbound radioligand was removed by rapid suction through 
glass fiber filters (see above) and rinsing three times with 4 ml 10 
mM Tris-HCl buffer (pH 7.5). Filter-bound radioactivity was counted 
in 3 ml of Beckman Ready Protein- cocktail using a Kontron MR 
300 liquid scintillation counter. 
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2.3. Assay for intracellular cyclic AMP 
Sterile hemolysis tubes were seeded with ~ 200 000 recombinant 
CHO cells in culture medium and incubated overnight at 37°C. The 
culture medium was then removed and replaced with 200 ul of 
HEPES-buffered Krebs-Ringer saline (KRH: 124 mM NaCl, 5 mM 
KC1, 1.25 mM MgS04, 1.5 mM CaCl2, 1.25 mM KH2P04, 25 mM 
HEPES, 8 mM glucose, 0.5 mg/ml BSA; pH 7.4) containing 0.1 uM 
adenine and 0.6 uCi [3H]adenine (0.85 TBq/mmole, Amersham). After 
1 h at 37°C, the cells were rinsed with 400 ul of KRH and 180 ul of 
fresh KRH was added to each tube. Intracellular accumulation of 
cAMP was initiated by the addition of 20 ul of KRH containing 
100 uM forskolin (Sigma), 1 mM 3-isobutyl-l-methylxanthine (Sig-
ma), 1 mM Ro20-1724 (Biomol. Res.), and the appropriate ligand(s) 
at 10-fold the desired final concentration. After exactly 10 min at 
37°C, the reaction was stopped by addition of 20 ul HC1 2.2 N and 
rapid mixing (Vortex). The [3H]cAMP content of each tube was de-
termined by selective batch elution on columns of 0.65 g alumina 
(activity grade 1, type WA-1: acid, Sigma) essentially as described 
by Alvarez and Daniels [14]. 
2.4. Unlabelled ligands 
Dynorphin A, nociceptin and the 20 'recombinant' peptides were 
synthesized using an automated peptide synthesizer (Applied Biosys-
tems model 433A). All the peptides had the expected molecular mass, 
as determined by mass spectrometry (Finnigan Mat model TSQ 700), 
and were > 90% pure, as judged by high performance liquid chroma-
tography (Waters Instruments). 
2.5. Analysis of the data 
Unweighed, nonlinear regression analysis of the data was per-
formed using InPlot ver 4.03 from GraphPad Software Inc., San Die-
go, CA, USA. 
3. Results 
The dynorphin A/nociceptin hybrid peptides (hereafter de-
noted dnl-dnlO) were generated by step wise replacement of 
dynorphin C-terminus with the corresponding nociceptin se-
quence. Likewise, the nociceptin/dynorphin A chimeric pepti-
des (hereafter denoted ndl-ndlO) were obtained by stepwise 
replacement of the nociceptin C-terminus by the correspond-
ing dynorphin A sequence. The two parent and 20 hybrid 
peptides were tested both for affinity and activity towards 
the ORL1 and K-opioid receptors, stably expressed in CHO 
cells. Peptide affinity was calculated from the capacity of the 
peptides to compete for equilibrium binding of 1 nM 
[3H]nociceptin (AD = 0.13 nM, [13,15]) (ORL1 receptor), and 
peptide 
Kj, log nM ED50, log nM 
-11-10-9 -8 -7 -6 -5 -4 -11-1 ' 
[unlabelled peptide], logM [peptide], logM 
Fig. 1. Comparison of the binding and biological potencies of noci-
ceptin and dynorphin A towards the ORL1 and K-opioid receptors. 
A: Inhibition by nociceptin (noc) and dynorphin A (dyn) of equili-
brium binding of [3H]nociceptin (1 nM) or [3H]diprenorphine (1 
nM), in a crude membrane fraction from recombinant CHO cells 
expressing the ORL1 or K-opioid (KOR) receptor, respectively. 
Each data point is the mean±s.e.m. of triplicate determinations. B: 
Inhibition by nociceptin (noc) and dynorphin A (dyn) of forskolin-
induced accumulation of cAMP in intact recombinant CHO cells ex-
pressing the ORL1 and K-opioid (KOR) receptors. Each data point 
is the mean±s.e.m. of triplicate determinations. 
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Fig. 2. Affinity (Ki, A and C) and activity (ED50, B and D) of the 
dn and nd series of chimeric peptides, towards the ORL1 (thick 
staircase line) and K-opioid (KOR, thin staircase line) receptors. 
Each step represents the mean of at least three values differing by 
less than 20%. Aj values were calculated from IC50 values obtained 
from competition curves such as those shown in Fig. 1A, using the 
Cheng and Prusoif equation [22]. EC5o values were obtained from 
inhibition experiments such as those shown in Fig. IB. The nocicep-
tin- and dynorphin-specific amino acid residues in the dn and hy-
brid peptides are shown in bold. Amino acid residues considered to 
be important for receptor-type selection are shadowed. 
of 1 nM [3H]diprenorphine (KB =0.3 nM) (K-opioid receptor). 
Activity was estimated from the ability of the peptides to half 
maximally inhibit forskolin-induced accumulation of cyclic 
AMP in recombinant CHO cells expressing the ORL1 or K-
opioid receptors. Fig. 1A shows that the ORL1 receptor binds 
nociceptin, its natural ligand, almost 1000-fold tighter (Ki: 
0.13 vs. 104 nM) than it does dynorphin A. Conversely, the 
K-opioid receptor binds dynorphin A, its natural ligand, with 
500-1000-fold the affinity (K{: 0.17 vs. 110 nM) it does noci-
ceptin. Likewise, Fig. IB shows that nociceptin is a potent 
ORL1 receptor agonist (ED5o: 0.8 nM) and is inactive to-
wards the K-opioid receptor (ED50 & 10 \xM) while, con-
versely, dynorphin A is a potent K-opioid receptor agonist 
(ED50: 0.56 nM) and is inactive at the ORL1 receptor 
(ED50 > 10 jiM). 
3.1. Binding properties and biological activity of the dynorphin/ 
nociceptin (dn) chimeric peptides 
In comparison with dynorphin A, the dnl hybrid peptide 
([Ala15]dynorphin A) showed a nearly 10-fold increased affin-
ity for both the ORL1 and K-opioid receptors (Fig. 2A and 
C). Further substitution of the C-terminal dynorphin sequence 
by that of nociceptin, such as in the dn2 through dn8 chime-
ras, resulted in no further change in binding affinity for either 
the ORL1 or the K-opioid receptors. In terms of biological 
activity, dynorphin A and the dnl through dn8 chimeras were 
equally highly potent K-opioid receptor agonists, with E50s in 
the range 0.3-1 nM, whereas they were inactive at the ORL1 
receptor (ED50S > 10 |J,M). The first dn hybrid peptide to ex-
hibit activity at the ORL1 receptor was dn9, i.e. dn8[Arg6-
Gly]. In comparison with dn8, dn9 displayed a dramatically 
increased (ED50: 25 vs. > 10000 nM) potency in the ORL1 
receptor-mediated cyclase inhibition assay. Moreover, the dn9 
chimera exhibited similarly high (nanomolar) affinities, and 
comparable biological activities towards the ORL1 (K\ = 2 
nM; ED5 0=25 nM) and K-opioid ( ^ = 0.8 nM; ED50 = 63 
nM) receptors. In this sense, the dn9 hybrid peptide behaved 
as a nonselective ('universal') agonist of the two types of re-
ceptor. Further substitution in dn9 of Leu5 by the threonyl 
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residue of nociceptin resulted in a chimeric pep tide (dnlO or 
[Tyr1]nociceptin) that showed reversed ORL1 vs. K-opioid re-
ceptor selectivity in comparison with dynorphin A and the 
dnl-8 chimeras. Overall, evolution of binding affinity with 
stepwise exchange of the C-terminus of dynorphin with that 
of nociceptin, paralleled well the change in biological activity, 
with a marked transition at the dn9 hybrid peptide, corre-
sponding to a reversal of receptor-type selectivity. 
3.2. Binding properties and biological activity of the nociceptin/ 
dynorphin (nd) chimeric peptides 
Progressive substitution of the nociceptin C-terminal amino 
acid residues by the corresponding residues of dynorphin A 
yielded hybrid peptides with progressively decreased yet in 
absolute terms high (K\ < 1 nM; ndl and nd2) to moderate 
(Kis in the range 10-70 nM; all others, nd7 excepted) affinities 
for the ORL1 receptor (Fig. 2B and D). Interestingly, the nd7 
chimera, the Arg8Gly 'mutant' of nd6, did not bind (Ki > 10 
|j.M) the ORL1 receptor. The decreased ORL1 receptor affin-
ity in the nd series of peptides was broadly paralleled by a 
progressively diminished biological potency. The correlation 
was however less than ideal since nd3, nd9 and ndlO had 
comparable affinities for the ORL1 receptor, yet nd3 showed 
substantial biological activity (ED50 = 38 nM) whereas nd9 
and ndlO were inactive (ED50 > 10 uM). 
Nociceptin and the ndl, nd2, nd4, nd5, nd6 and nd8 chi-
meras had similar, although low (Kj& in the range 30-200 nM) 
affinities for the K-opioid receptor, whereas, nd3 (nd2[Ar-
gl2Leu]) and nd7 (nd6[Arg8Ile]) did not bind this receptor. 
None of the ndl-nd8 hybrid peptides displayed measurable 
activity in the K-opioid receptor-mediated cyclase inhibition 
assay. The first nd chimera to show nanomolar (K\ = 2.5 
nM) affinity albeit with low biological potency for the K-
opioid receptor was nd9 (nd8[Gly6Arg]). Interestingly, K-
opioid receptor activity, but not affinity, was further aug-
mented (~ 10-fold) in ndlO ([Phe^dynorphin A). No 'univer-
sal' (nonselective) and potent agonist of the ORL1 and K-
opioid receptors could be identified in the nd series of hybrid 
peptides. 
4. Discussion 
Dynorphin A-(l-13), which is equipotent with dynorphin 
A-(l-17) in the guinea pig ileum bioassay [16], has been sug-
gested to consist of two distinct domains: a 'message' domain, 
Tyr^Gly-Gly-Phe, the shortest fragment with naloxone-rever-
sible opioid activity, and a potency-enhancing, 'address' do-
main, Leu5-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys, in which Arg7 
makes the greatest contribution [17]. Recently, it was pro-
posed that a necessary and sufficient requirement for a peptide 
to bind the K-opioid receptor with high specificity is the pres-
ence of the N-terminal Tyr-Gly-Gly-Phe-Met or Leu opioid 
core plus an Arg-X extension [18]. In comparison with dynor-
phin A, dynorphin A-(l-7) displays the same affinity for the K-
opioid receptor and the same opioid receptor-type selectivity 
[18], and only moderately ( < 10-fold) reduced biological po-
tency [17], indicating that the C-terminal decapeptide section 
does not play a too critical role in dynorphin occupancy and 
activation of the receptor. Consistent with this conclusion is 
the present finding that exchange of the C-terminal 11-mer of 
dynorphin by the corresponding nociceptin sequence compris-
ing just three common residues (Lys13, Asn16 and Gin17), re-
sults in a chimeric peptide, dn8 (YGGFLR/ARKSAR-
KLANQ), whose binding and activity towards the K-opioid 
receptor are identical with those of dynorphin A. 
With regard to nociceptin, the necessary and sufficient re-
quirements for selective and potent peptide binding to the 
ORL1 receptor are yet to be identified. It has been found 
that nociceptin-(l-13)-NH2 (which is somewhat longer than 
the smallest fully active fragment of dynorphin A, see above) 
has the same binding [19] and biological [20] potencies as 
nociceptin towards the ORL1 receptor. Furthermore, evidence 
has now accumulated that its N-terminal residues play an 
important role in nociceptin occupation and stimulation of 
the ORL1 receptor: deleting Phe1 [15], or replacing Phe1, 
Gly2 or Phe4 by an alanyl residue [19,21], inactivates the pep-
tide. However, mutations of more internal residues, particu-
larly Arg8 and Arg12, also adversely affect nociceptin affinity 
and activity towards the ORL1 receptor ([19,21], and the 
present data). Indeed, comparison of the structure-activity 
relationships of nociceptin and dynorphin A has led most 
investigators to suggest that the two peptides have different 
functional architectures [15,20,21]. Our data obtained with the 
nd series of hybrid peptides lend considerable weight to this 
conclusion. Had the functional architecture of nociceptin been 
equivalent to that of dynorphin A, the binding and activity 
profiles of the nd series of chimeric peptides should have been 
exactly mirrored by the dn series. This is clearly not the case 
since progressive replacement of the dynorphin C-terminus by 
that of nociceptin (dn series) adversely affected affinity for the 
K-opioid receptor only 'late' (dn9) in the series, whereas ex-
change of the nociceptin C-terminus with the analogous sec-
tion in dynorphin (nd series) adversely affected affinity for the 
ORL1 receptor at a much 'earlier' point (nd3) in the series. 
This suggests that the (T)GARKSAR(K) nociceptin sequence 
delimited approximately by the dn9 and nd3 hybrid peptides 
endows nociceptin with affinity and activity towards the 
ORL1 receptor. Particularly important in this sequence is 
the Arg8 residue since moving from nd6 to nd7 (nd6[Arg8Ile]) 
effectively abolishes binding to the ORL1 receptor. This is in 
keeping with the earlier demonstration that [Ala8]nociceptin 
has only 0.3% the affinity of nociceptin for ORL1 [19]. An 
intriguing observation is that the nd3-nd6 and the dn3-dn8 
chimeras display comparable apparent affinities for the ORL1 
receptor, yet only the former are biologically active. A plau-
sible explanation is that the nd3-nd6, but not the dn3-dn8 
chimeras have access to the ORL1 receptor signal transduc-
tion apparatus, implying that the two series of hybrid peptides 
bind the ORL1 receptor in a different way. 
Another interesting observation here, using the 'recombi-
nant' peptide approach, is that identified nociceptin and dy-
norphin A residues are critical not only for potency but also 
for receptor-type selection. Indeed, the dn8 and dnlO hybrid 
peptides, whose primary structures differ only at positions 5 
and 6, show reciprocal ORL1 and K-opioid receptor selectiv-
ity. Dn8 contains the dynorphin Leu5-Arg6 sequence and pre-
fers the K-opioid receptor, whereas dnlO contains the nocicep-
tin Thr5-Gly6 sequence and prefers the ORL1 receptor. 
Likewise, dn9 (YGGFL/GARKSARKLANQ) contains the 
mixed Leu5-Gly6 sequence and binds and activates the two 
types of receptor equally well. The Leu5-Arg6 and Thr5-Gly6 
'hinge' sequences may therefore be important in specifying 
dynorphin K-opioid/ORLl, and nociceptin ORLl/K-opioid re-
ceptor selectivity, respectively. Whether or not the ORL1 re-
336 S. Lapalu et al.lFEBS Letters 417 (1997) 333-336 
ceptor will accept peptides lacking a glycine at position 6 
remains speculative, although a similar requirement for an 
arginine at the same position in opioid peptides has been 
advanced for the K-opioid receptor [18]. 
Based upon the present and previous [15-21] data, the N-
terminal heptapeptide appears to be both necessary and suffi-
cient for dynorphin A to selectively bind and activate the K-
opioid receptor. This requirement is not however sufficient for 
nociceptin to selectively bind and activate the ORL1 receptor. 
Nociceptin needs an additional, highly positively charged 
(Arg+-Lys+-Ser-Ala-Arg+-Lys+) extension, in order to dis-
play biological activity. The K-opioid receptor site may thus 
be viewed as comprising two functional domains: a trans-
membrane opioid binding pocket that recognizes the Tyr1-
Gly-Gly-Phe opioid 'message', and an acidic second extracel-
lular loop, not present in the u, and 8 receptors, that interacts 
with the positively charged amino acid residues at positions 6 
and 7 (the potency- and selectivity-enhancing 'address'), of 
dynorphin [18]. Likewise, the ORL1 receptor can be function-
ally compartmentalized in terms of a structurally related bind-
ing pocket [15] able to recognize the nociceptin Phe^Gly-Gly-
Phe 'message', and a highly acidic second extracellular loop 
interacting with the positively charged residues at positions 8, 
9, 12 and 13 ('address') of nociceptin. According to this view, 
the two neuropeptides possess very similar functional archi-
tectures, differing only in the length of their 'address' sequen-
ces. This notion is however untenable since several of our nd 
hybrid peptides, whilst they contain the Phe^Gly-Gly-Phe 
sequence, are totally inactive at the ORL1 receptor. In 
marked contrast, the dn chimeras, which all contain the 
Tyr^Gly-Gly-Phe opioid 'message' sequence, are all active 
at the K-opioid receptor. Clearly, the 'message' and 'address' 
partition of dynorphin does not apply to nociceptin. Notwith-
standing the dual structural homology of peptide ligands and 
receptors, these findings imply that either dynorphin A and 
nociceptin bind the K-opioid and ORL1 receptors in a differ-
ent way, respectively, or that the dynorphin A (K-opioid) and 
nociceptin (ORL1) receptor sites are not equivalent. Determi-
nation of the bioactive (receptor-bound) conformation of the 
two neuropeptides will be necessary to answer this fundamen-
tal question. 
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